Trial success for sanofi’s once-daily diabetes treatment

 Lixisenatide once-daily has been proven to be equally as effective as the current licensed twice-daily therapy in treating type 2 diabetes.

A recent Phase III trial also showed that lixisenatide caused fewer hypoglycaemic events than another GLP-1 receptor agonist, exenatide (Byetta) twice-daily (8 vs. 48 events).

The primary endpoint of the GetGoal-X Phase III study of lixisenatide was non-inferiority in HbA1c reduction from baseline, when used as add-on therapy for people with type 2 diabetes whose condition was inadequately controlled by metformin.

Dr Andrew Hockey (pictured), Director of Medical Operations, sanofi-aventis UK, commented: “The lixisenatide clinical development programme exemplifies our commitment to people with diabetes and our ambition to help them manage their condition more effectively.”

A total of 639 people were involved in the GetGoal-X clinical trial, which had a 24-week main treatment period.